German Government Joins Superbug Fight With €40m CARB-X Investment
Executive Summary
Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.
You may also be interested in...
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline
Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Four Early-Stage Antibacterial Drugs To Watch: Highlights From IDWeek
Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.